Transfusion-related immunomodulation by platelets is dependent on their expression of MHC Class I molecules and is independent of white cells

Transfusion

Volumn 48, Issue 9, 2008, Pages 1778-1786

  Aslam, Rukhsana ^b   Speck, Edwin R ^b   Kim, Michael ^b   Freedman, John ^b   Semple, John W ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD STORAGE; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOMODULATION; LEUKOCYTE; MOUSE; NONHUMAN; SKIN GRAFT; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED IMMUNOMODULATION;

ANIMALS; BLOOD PLATELETS; HISTOCOMPATIBILITY ANTIGENS CLASS I; LEUKOCYTES; MICE; MODELS, ANIMAL; PLATELET TRANSFUSION;

EID: 50849142515     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01791.x     Document Type: Article

References (43)

1. Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of t cell recognition of alloantigen. The role of peptides. Transplantation 1994 57 : 1295 302.
2. Semple JW, Freedman J. The basic immunology of platelet-induced alloimmunization. In : Kickler TS, Herman JH, editors. Current issues in platelet transfusion therapy and platelet alloimmunity. Bethesda, MD : American Association of Blood Banks 1999. p. 77 101.
3. Merryman HT. Transfusion-induced alloimmunization and immunosuppression and the effects of leukocyte depletion. Transfus Med Rev 1989 3 : 180 93.
4. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997 337 : 1861 915.
5. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973 5 : 253 9.
6. Lenhard V, Mytilineos J, Opelz G. Immunomodulation after blood transfusion in the rat. Transplant Proc 1987 19 1 Pt 2 1437 8.
7. Ludwin D, Stary S, Singal DP. Suppressor cell generation in mice after blood transfusions from different H-2 donors. Transplant Proc 1987 21 : 3402 5.
8. Quigley RL, Wood KJ, Morris PJ. Transfusion induces blood donor-specific suppressor cells. J Immunol 1989 142 : 463 70.
9. Bordin JO, Bardossy L, Blajchman MA. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. Blood 1994 84 : 344 8.
10. Rustoven JJ. Blood transfusion and cancer: clinical studies. In : Singal DP, editor. Immunological effects of blood transfusion. Boca Raton, FL : CRC press 1995. p. 85 110.
11. Tartter PI. Blood transfusion and bacterial infections: clinical studies. In : Singal DP, editor. Immunological effects of blood transfusion. Boca Raton, FL : CRC press 1995. p. 111 26.
12. Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999 39 : 665 70.
13. Jensen LS, Andersen AJ, Christiansen PM, Hokland P, Juhl CO, Madsen G, Mortensen J, Møller-Nielsen C, Hanberg-Sørensen F, Hokland M. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992 79 : 513 6.
14. Houbiers JG, Brand A, van de Watering LM, Hermans J, Verwey PJ, Bijnen AB, Pahlplatz P, Schattenkerk ME, Wobbes T, de Vries JE, Klementschitsch P, van de Maas AH, van de Velde CJ. Randomized controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994 344 : 573 8.
15. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Quist N. Randomized comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996 348 : 841 5.
16. van de Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, Harvey MS, Huysmans HA, Brand A. Beneficial effect of leukocyte depletion of transfused blood on post-operative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998 97 : 562 8.
17. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2007 3 : 17804128.
18. Vamvakas EC. White-blood-cell-containing allogeneic blood transfusion and postoperative infection or mortality: an updated meta-analysis. Vox Sang 2007 92 : 224 32.
19. Vamvakas EC. Why have meta-analyses of randomized controlled trials of the association between non-white-blood-cell-reduced allogeneic blood transfusion and postoperative infection produced discordant results? Vox Sang 2007 93 : 196 207.
20. Bijnen AB, Heineman E, Marquet RL, Niessen GJ, Obertop H, Tank B, Jeekel J. Lack of beneficial effect of thrombocyte transfusions on the kidney graft survival in dogs. Transplantation 1984 37 : 213 4.
21. Chapman JR, Ting A, Fisher M, Carter NP, Morris PJ. Failure of platelet transfusion to improve human renal allograft survival. Transplantation 1986 41 : 468 73.
22. Oh JH, McClure HM, Tuttle EP. Immunological unresponsiveness induced by platelet transfusions in rhesus monkeys. Transplantation 1983 36 : 727 32.
23. Slichter SJ, Fish D, Abrams VK, Gaur L, Nelson K, Bolgiano B. Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model. Blood 2005 105 : 847 54.
24. Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, Indiveri F, Puppo F. Soluble HLA Class I, HLA Class II, and Fas Ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999 93 : 1770 7.
25. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003 33 : 125 34.
26. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, Ni H, Lazarus AH, Freedman J, Semple JW. Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006 107 : 637 41.
27. Semple JW, Speck ER, Cosgrave Lazarus AH, Blanchette V, Freedman J. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood 1999 93 : 713 20.
28. Bertoni R, Sette A, Sidney J, Guidotti LG, Shapiro M, Purcell R, Chisari FV. Human class I supertypes and CTL repertoires extend to chimpanzees. J Immunol 1998 161 : 4447 55.
29. Bang KW, Speck ER, Blanchette VS, Freedman J, Semple JW. Unique processing pathways within recipient antigen presenting cells determine IgG immune responsiveness against donor platelet MHC antigens. Blood 2000 95 : 1735 42.
30. Steinmuller D. Skin grafting. Surgical techniques in immunology. Methods Immunol 1984 108 : 20 7.
31. Valujskikh A, Matesic D, Heeger PS. Characterization and manipulation of T cell immunity to skin grafts expressing a transgenic minor antigen. Transplantation 1999 68 : 1029 36.
32. Santoso S, Mueller-Eckhardt G, Santoso S, Kiefel V, Mueller-Eckhardt C. HLA antigens on platelet membranes. In vitro and in vivo studies. Vox Sang 1986 51 : 327 33.
33. Kao KJ, Scornik JC, Riley WJ, McQueen CF. Association between HLA phenotypes and HLA concentration in plasma or platelets. Hum Immunol 1988 21 : 115 21.
34. Sugawara S, Abo T, Kumagai K. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3.0. J Immunol Methods 1987 100 : 83 8.
35. Kurata Y, Oshida M, Take H. New approach to eliminating HLA class I antigens from platelet surface without cell damage: acid treatment at pH 3.0. Vox Sang 1989 57 : 199 206.
36. Novotny VM, Huizinga TW, van Doorn R, Briet E, Brand A. HLA class I-eluted platelets as an alternative to HLA matched platelets. Transfusion 1996 36 : 388 91.
37. Castro E, Muncunill J, Barea L, Gonzalez R, Fernandez-Villalta MJ. Acid elution of platelets HLA-class I antigens in the treatment of a refractory patient. Br J Haematol 1998 100 : 245 6.
38. Rosenberg AS, Mizuochi T, Singer A. Evidence for involvement of dual-function T cells in rejection of MHC class I disparate skin grafts. Assessment of MHC class I alloantigens as in vivo helper determinants. J Exp Med 1988 168 : 33 45.
39. Auchincloss H Jr., Lee R, Shea S, Markowitz JS, Grusby MJ, Glimcher LH. The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci U S A 1993 90 : 3373 7.
40. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, Stein CS, Nieswandt B, Wang Y, Davidson BL, Ratliff TL. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003 19 : 9 19.
41. Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, Chisari FV, Ruggeri ZM, Guidotti LG. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 2005 11 : 1167.
42. Gouttefangeas C, Diehl M, Keilholz W, Hörnlein RF, Stevanovic S, Rammensee HG. Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro. Blood 2000 95 : 3168 75.
43. Sayeh E, Sterling K, Speck E, Freedman J, Semple JW. IgG anti-platelet immunity is dependent on an early innate natural killer cell-derived interferon-gamma response that is regulated by CD8+ T cells. Blood 2004 103 : 2705 9.